American Chemical Society--236th National Meeting & Exposition. Compound development for prevalent conditions.
Burt
Jessica
J
Thomson Reuters, 77 Hatton Garden, London, EC1N 8JS, UK. jessica.burt@thomsonreuters.com
Chu
Magdalene
M
D000581:Amidohydrolases / Q000037:antagonists & inhibitors; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D019440:Anti-Obesity Agents / Q000494:pharmacology; D000970:Antineoplastic Agents / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000494:pharmacology; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D019007:P-Selectin / Q000187:drug effects; D054510:Phospholipases A2, Cytosolic / Q000037:antagonists & inhibitors; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D012702:Serotonin Antagonists / Q000494:pharmacology; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology; D017381:Spliceosomes / Q000187:drug effects; D000099252:Fatty Acid Amide Hydrolases
D000581:Amidohydrolases; D000700:Analgesics; D000893:Anti-Inflammatory Agents; D019440:Anti-Obesity Agents; D000970:Antineoplastic Agents; D014150:Antipsychotic Agents; D000995:Antitubercular Agents; D004791:Enzyme Inhibitors; D019007:P-Selectin; D054510:Phospholipases A2, Cytosolic; D043884:Receptor, Cannabinoid, CB1; D012702:Serotonin Antagonists; D017367:Selective Serotonin Reuptake Inhibitors; D000099252:Fatty Acid Amide Hydrolases